Insmed Incorporated
US ˙ NasdaqGS ˙ US4576693075

Introduction

This page provides a comprehensive analysis of the known insider trading history of David W J Mcgirr. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David W J Mcgirr has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RYTM / Rhythm Pharmaceuticals, Inc. Director 7,000
US:US98420X1110 / X4 PHARMACEUTICALS INC WARRANTS EXP 4/12/24 0.00000000 Director 4,722
US:INSM / Insmed Incorporated Director 97,723
US:VYNE / VYNE Therapeutics Inc. Director 65,780
US:ROKA / Roka Bioscience, Inc. Director 3,000
US:RLYP / Relypsa, Inc. Director 0
US:CBST / SVP & Chief Financial Officer 4,500
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David W J Mcgirr. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases INSM / Insmed Incorporated - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INSM / Insmed Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INSM / Insmed Incorporated Insider Trades
Insider Sales INSM / Insmed Incorporated - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INSM / Insmed Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INSM / Insmed Incorporated Insider Trades
Insider Purchases RYTM / Rhythm Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INSM / Insmed Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insider Sales RYTM / Rhythm Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INSM / Insmed Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RYTM / Rhythm Pharmaceuticals, Inc. Insider Trades
Insider Purchases VYNE / VYNE Therapeutics Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in INSM / Insmed Incorporated. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VYNE / VYNE Therapeutics Inc. Insider Trades
Insider Sales VYNE / VYNE Therapeutics Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in INSM / Insmed Incorporated. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VYNE / VYNE Therapeutics Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David W J Mcgirr as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-23 2025-06-18 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
M - Exercise 4,000 7,000 133.33
2025-06-10 2025-06-09 4 XFOR X4 Pharmaceuticals, Inc
Common Stock
A - Award 1,500 4,722 46.55
2025-06-05 2025-06-03 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -9,873 3,000 -76.70 65.64 -648,090 196,928
2025-06-05 2025-06-03 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
S - Sale X -55,558 12,873 -81.19 65.15 -3,619,404 838,630
2025-06-05 2025-06-03 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
M - Exercise 65,431 68,431 2,181.03 4.59 300,328 314,098
2025-06-04 2025-06-04 4 INSM INSMED Inc
Common Stock
S - Sale X -3,000 97,723 -2.98 73.27 -219,810 7,160,164
2025-06-04 2025-06-03 4 INSM INSMED Inc
Common Stock
S - Sale X -3,250 100,723 -3.13 71.30 -231,725 7,181,550
2025-05-19 2025-05-15 4 INSM INSMED Inc
Common Stock
A - Award 5,058 103,973 5.11
2024-06-25 2024-06-21 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Common Stock
M - Exercise 3,000 3,000
2024-06-11 2024-06-10 4 XFOR X4 Pharmaceuticals, Inc
Common Stock
A - Award 45,000 96,667 87.10
2024-05-15 2024-05-13 4 INSM INSMED Inc
Common Stock
A - Award 13,162 98,915 15.35
2023-06-14 2023-06-13 4 XFOR X4 Pharmaceuticals, Inc
Common Stock
A - Award 45,000 51,667 674.97
2023-05-15 2023-05-11 4 INSM INSMED Inc
Common Stock
A - Award 13,192 85,753 18.18
2022-06-27 2022-06-06 4 XFOR X4 Pharmaceuticals, Inc
Common Stock
A - Award 6,667 6,667
2022-05-13 2022-05-11 4 INSM INSMED Inc
Common Stock
A - Award 14,645 72,561 25.29
2021-06-11 2021-06-09 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 15,000 15,000
2021-06-02 2021-06-02 4 XFOR X4 Pharmaceuticals, Inc
Stock Option (right to buy)
A - Award 6,000 6,000 9.50 57,000 57,000
2021-05-14 2021-05-12 4 INSM INSMED Inc
Common Stock
A - Award 7,558 57,916 15.01
2020-06-18 2020-06-17 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 18,500 18,500
2020-06-11 2020-06-10 4 XFOR X4 Pharmaceuticals, Inc
Stock Option (right to buy)
A - Award 3,427 3,427
2020-05-14 2020-05-12 4 INSM INSMED Inc
Common Stock
A - Award 8,097 50,358 19.16
2019-08-08 2019-06-25 4/A MNLO Menlo Therapeutics Inc.
Stock Option
A - Award 22,500 65,780 51.99
2019-06-27 2019-06-25 4 MNLO Menlo Therapeutics Inc.
Stock Option
A - Award 22,500 65,780 51.99
2019-06-21 2019-06-19 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 15,000 15,000
2019-06-19 2019-06-17 4 XFOR X4 Pharmaceuticals, Inc
Stock Option (right to buy)
A - Award 3,427 3,427
2019-05-16 2019-05-15 4 INSM INSMED Inc
Common Stock
A - Award 6,899 42,261 19.51
2018-06-08 2018-06-06 4 RYTM RHYTHM PHARMACEUTICALS, INC.
Stock Option (right to buy)
A - Award 10,000 10,000
2018-06-07 2018-06-05 4 ASNS Arsanis, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2018-05-17 2018-05-15 4 INSM INSMED Inc
Common Stock
A - Award 6,066 35,362 20.71
2018-03-05 2017-11-15 4/A ASNS Arsanis, Inc.
Stock Option (right to buy)
A - Award 25,000 25,000
2017-12-01 2017-11-15 4 ASNS Arsanis, Inc.
Stock Option (right to buy)
A - Award 7,324 7,324
2017-06-30 2017-06-28 4 ROKA Roka BioScience, Inc.
Stock Option (right to buy)
A - Award 3,000 3,000
2017-05-19 2017-05-17 4 INSM INSMED Inc
Common Stock
A - Award 6,702 29,296 29.66
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Stock Option (Right to Buy)
D - Sale to Issuer -4,500 0 -100.00
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Stock Option (Right to Buy)
D - Sale to Issuer -4,500 0 -100.00
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Stock Option (Right to Buy)
D - Sale to Issuer -3,828 0 -100.00
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Stock Option (Right to Buy)
D - Sale to Issuer -10,140 0 -100.00
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Stock Option (Right to Buy)
D - Sale to Issuer -55,232 0 -100.00
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Common Stock
D - Sale to Issuer -2,250 0 -100.00 32.00 -72,000
2016-09-02 2016-09-01 4 RLYP Relypsa Inc
Common Stock
U - Other -2,729 2,250 -54.81 32.00 -87,328 72,000
2016-06-24 2016-06-22 4 ROKA Roka BioScience, Inc.
Stock Option (right to buy)
A - Award 30,000 30,000
2016-06-23 2016-06-21 4 RLYP Relypsa Inc
Stock Option (Right to Buy)
A - Award 4,500 4,500
2016-06-23 2016-06-21 4 RLYP Relypsa Inc
Common Stock
A - Award 2,250 4,979 82.45
2016-06-08 2016-06-07 4 RLYP Relypsa Inc
Common Stock
S - Sale -1,013 2,729 -27.07 19.34 -19,588 52,770
2016-05-23 2016-05-19 4 INSM INSMED Inc
Common Stock
A - Award 12,742 22,594 129.33
2015-06-26 2015-06-24 4 ROKA Roka BioScience, Inc.
Stock Option (right to buy)
A - Award 15,000 15,000
2015-06-15 2015-06-11 4 RLYP Relypsa Inc
Common Stock
S - Sale X -1,220 3,742 -24.59 34.67 -42,300 129,744
2015-06-09 2015-06-04 4 RLYP Relypsa Inc
Stock Option (right to buy)
A - Award 4,500 4,500
2015-06-09 2015-06-04 4 RLYP Relypsa Inc
Common Stock
A - Award 2,250 4,962 82.96
2015-01-09 2015-01-08 4 INSM INSMED Inc
Common Stock
A - Award 6,222 9,852 171.40
2014-11-17 2014-11-17 4 ROKA Roka BioScience, Inc.
Common Stock
P - Purchase 20,994 50,000 72.38 3.65 76,697 182,665
2014-11-17 2014-11-14 4 ROKA Roka BioScience, Inc.
Common Stock
P - Purchase 29,006 29,006 3.57 103,424 103,424
2014-11-04 2014-10-31 4 INSM INSMED Inc
Restricted Stock Units
M - Exercise -702 0 -100.00
2014-11-04 2014-10-31 4 INSM INSMED Inc
Common Stock
M - Exercise 702 3,630 23.98
2014-06-23 2014-06-19 4 RLYP Relypsa Inc
Stock Option (right to buy)
A - Award 3,828 3,828
2014-06-23 2014-06-19 4 RLYP Relypsa Inc
Common Stock
A - Award 2,712 2,712
2014-01-14 2014-01-10 4 INSM INSMED INC
Common Stock
A - Award 2,928 3,630 417.09
2013-11-01 2013-10-31 4 INSM INSMED INC
Restricted Stock Units
A - Award 702 702
2013-02-20 2013-02-16 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -1,500 4,500 -25.00
2013-02-20 2013-02-16 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 1,500 18,700 8.72
2013-02-20 2013-02-15 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
A - Award 4,807 4,807
2012-09-24 2012-09-21 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -15,000 10,000 -60.00
2012-09-24 2012-09-21 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -15,000 17,200 -46.58 49.79 -746,850 856,388
2012-09-24 2012-09-21 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 15,000 32,200 87.21 10.35 155,250 333,270
2012-08-27 2012-08-24 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -20,000 25,000 -44.44
2012-08-27 2012-08-24 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -20,000 17,200 -53.76 45.69 -913,870 785,928
2012-08-27 2012-08-24 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 20,000 37,200 116.28 10.35 207,000 385,020
2012-05-16 2012-05-15 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -1,600 1,600 -50.00
2012-05-16 2012-05-15 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 1,600 22,480 7.66
2012-05-16 2012-05-14 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -1,875 3,750 -33.33
2012-05-16 2012-05-14 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 1,875 20,880 9.87
2012-05-15 2012-05-13 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
M - Exercise -1,400 4,200 -25.00
2012-05-15 2012-05-13 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 1,400 19,005 7.95
2012-04-03 2012-03-30 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
J - Other 260 17,605 1.50 43.25 11,245 761,416
2012-02-27 2012-02-23 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
M - Exercise -15,000 0 -100.00
2012-02-27 2012-02-23 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
S - Sale -15,000 17,345 -46.38 42.68 -640,185 740,267
2012-02-27 2012-02-23 4 CBST CUBIST PHARMACEUTICALS INC
Common Stock
M - Exercise 15,000 32,345 86.48 12.61 189,150 407,870
2012-02-21 2012-02-16 4 CBST CUBIST PHARMACEUTICALS INC
Restricted Stock Units
A - Award 6,000 6,000
2012-02-21 2012-02-16 4 CBST CUBIST PHARMACEUTICALS INC
Stock Options (Right to Buy)
A - Award 37,500 37,500
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)